KRAS and lung carcinoma: The majority of what is known about PTEN and TRP53 results from KRAS-mutant lung cancer models; thus, it is critical to better understand the effects of these tumor suppressors in the context of SOX2 overexpression, which may have greater relevance to patients with LUSC.